Trial Profile
A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate; Vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms HZ-COPD-Mortality; SUMMIT
- Sponsors GlaxoSmithKline; GSK
- 03 Apr 2023 Results developing machine learning (ML) models which estimate individual treatment effect of an intervention using data from NCT01313676 and NCT02164513, published in the Thorax
- 21 Oct 2020 Results of post hoc subgroup analysis presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 04 Sep 2018 Results (n=16485) published in the Journal of the American College of Cardiology.